1. Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009; 62(2): 105-8.
  2. Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013; 75(4): 392-6.
  3. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017; 12(1): 43.
  4. Harvey NC, McCloskey E, Kanis JA, Compston J, Cooper C. Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464). Osteoporos Int 2018; 29(7): 1511-3.
  5. Söreskog E, Lindberg I, Kanis JA, et al. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporos Int 2021; 32(3): 585-94.
  6. Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9(8): 1137-41.
  7. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001; 29(6): 517-22.
  8. Borgström F, Karlsson L, Ortsäter G, et al. Fragility fractures in Europe: burden, management and opportunities. Archives of Osteoporosis 2020; 15(1): 59.
  9. Wainwright SA, Marshall LM, Ensrud KE, et al. Hip Fracture in Women without Osteoporosis. Journal of Clinical Endocrinology Metabolism 2005; 90(5): 2787-93.
  10. Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34(1): 195-202.
  11. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18(8): 1033-46.
  12. Royal College of Physicians. National Hip Fracture Database Annual Report., 2019.
  13. NHS National Services Scotland. Scottish Hip Fracture Audit. Hip Fracture Care Pathway Report 2019., 2019.
  14. Al-Sari UA, Tobias J, Clark E. Health-related quality of life in older people with osteoporotic vertebral fractures: a systematic review and meta-analysis. Osteoporos Int 2016; 27(10): 2891-900.
  15. Griffin XL, Parsons N, Achten J, Fernandez M, Costa ML. Recovery of health-related quality of life in a United Kingdom hip fracture population. The Warwick Hip Trauma Evaluation--a prospective cohort study. Bone Joint J, 2015; 97-b(3): 372-82.
  16. Leal J, Gray AM, Prieto-Alhambra D, et al. Impact of hip fracture on hospital care costs: a population-based study. Osteoporos Int 2016; 27(2): 549-58.
  17. Kanis JA, Norton N, Harvey NC, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 2021;
  18. Royal College of Physicians. National Hip Fracture Database Annual Report., 2018.
  19. Royal College of Physicians. The challenge of the next decade: are hip fracture services ready? A review of data from the National Hip Fracture Database (January–December 2019). London: RCP, 2021.
  20. Hawley S, Javaid MK, Prieto-Alhambra D, et al. Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing 2016; 45(2): 236-42.
  21. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama 2009; 301(5): 513-21.
  22. Johnell O, Kanis JA, Odén A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004; 15(1): 38-42.
  23. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone 2003; 32(5): 468-73.
  24. Bhimjiyani A, Neuburger J, Jones T, Ben-Shlomo Y, Gregson CL. The effect of social deprivation on hip fracture incidence in England has not changed over 14 years: an analysis of the English Hospital Episodes Statistics (2001-2015). Osteoporos Int 2018; 29(1): 115-24.
  25. Bhimjiyani A, Neuburger J, Jones T, Ben-Shlomo Y, Gregson CL. Inequalities in hip fracture incidence are greatest in the North of England: regional analysis of the effects of social deprivation on hip fracture incidence across England. Public Health 2018; 162: 25-31.
  26. Curtis EM, van der Velde R, Moon RJ, et al. Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status. Bone 2016; 87: 19-26.
  27. van der Velde RY, Wyers CE, Curtis EM, et al. Secular trends in fracture incidence in the UK between 1990 and 2012. Osteoporosis International 2016; 27(11): 3197-206.
  28. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312(7041): 1254-9.
  29. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20(7): 1185-94.
  30. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359(9321): 1929-36.
  31. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. OsteoporosInt 2000; 11(3): 192-202.
  32. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008; 42(3): 467-75.
  33. De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998; 13(10): 1587-93.
  34. Binkley N, Adler R, Bilezikian JP. Osteoporosis diagnosis in men: the T-score controversy revisited. Curr Osteoporos Rep 2014; 12(4): 403-9.
  35. International Society for Clinical Densitometry (ISCD). Adult Official Positions of the ISCD., 2019.
  36. Kanis JA, Johnell O, Oden A, et al. The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int 2006; 17(4): 527-34.
  37. Leslie WD, Tsang JF, Caetano PA, Lix LM. Number of osteoporotic sites and fracture risk assessment: a cohort study from the Manitoba Bone Density Program. J Bone Miner Res 2007; 22(3): 476-83.
  38. Leslie WD, Martineau P, Bryanton M, Lix LM. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study. Osteoporos Int 2019; 30(7): 1445-53.
  39. Royal Osteoporosis Society. Reporting dual energy X-ray absorptiometry scans in adult fracture risk assessment: Standards for quality. , 2019.
  40. Adams AL, Fischer H, Kopperdahl DL, et al. Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). J Bone Miner Res 2018; 33(7): 1291-301.
  41. Johannesdottir F, Allaire B, Bouxsein ML. Fracture Prediction by Computed Tomography and Finite Element Analysis: Current and Future Perspectives. Curr Osteoporos Rep 2018; 16(4): 411-22.
  42. Pickhardt PJ, Bodeen G, Brett A, Brown JK, Binkley N. Comparison of femoral neck BMD evaluation obtained using Lunar DXA and QCT with asynchronous calibration from CT colonography. J Clin Densitom 2015; 18(1): 5-12.
  43. Cann CE, Adams JE, Brown JK, Brett AD. CTXA hip--an extension of classical DXA measurements using quantitative CT. PloS one 2014; 9(3): e91904-e.
  44. Ziemlewicz TJ, Maciejewski A, Binkley N, Brett AD, Brown JK, Pickhardt PJ. Opportunistic Quantitative CT Bone Mineral Density Measurement at the Proximal Femur Using Routine Contrast-Enhanced Scans: Direct Comparison With DXA in 355 Adults. J Bone Miner Res 2016; 31(10): 1835-40.
  45. Lenchik L, Weaver AA, Ward RJ, Boone JM, Boutin RD. Opportunistic Screening for Osteoporosis Using Computed Tomography: State of the Art and Argument for Paradigm Shift. Current rheumatology reports 2018; 20(12): 74.
  46. Kanis JA on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK, Sheffield 2008, 2007.
  47. Laet C, Kanis J, Oden A, et al. Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporosis International 2005; 16(11): 1330-8.
  48. Leslie WD, Schousboe JT, Morin SN, et al. Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. Osteoporos Int 2020; 31(6): 1059-67.
  49. Kanis J, Johnell O, Laet CD, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35: 375-82.
  50. Johansson H, Odén A, McCloskey EV, Kanis JA. Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporosis International 2014; 25(1): 235-41.
  51. Kanis JA, Johansson H, Odén A, et al. Characteristics of recurrent fractures. Osteoporos Int 2018; 29(8): 1747-57.
  52. Kanis JA, Johansson H, Harvey NC, et al. Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int 2020; 31(10): 1817-28.
  53. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone 2004; 35(5): 1029-37.
  54. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005; 16(2): 155-62.
  55. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39(12): 1383-9.
  56. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Mineral Research: 2004; 19(6): 893-9.
  57. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005; 16(7): 737-42.
  58. Vilaca T, Schini M, Harnan S, et al. The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update. Bone 2020; 137: 115457.
  59. Bai J, Gao Q, Wang C, Dai J. Diabetes mellitus and risk of low-energy fracture: a meta-analysis. Aging clinical and experimental research 2020; 32(11): 2173-86.
  60. Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. Journal of Bone and Mineral Research 2012; 27: 2231-7.
  61. Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. Journal of Bone and Mineral Research 2012; 27(2): 301-8.
  62. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E. BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 2009; 20(10): 1675-82.
  63. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. FRAX(®) with and without bone mineral density. Calcif Tissue Int 2012; 90(1): 1-13.
  64. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344(5): 333-40.
  65. Mortensen SJ, Mohamadi A, Wright CL, et al. Medications as a Risk Factor for Fragility Hip Fractures: A Systematic Review and Meta-analysis. Calcif Tissue Int 2020; 107(1): 1-9.
  66. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int 2007; 81(3): 153-61.
  67. Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Osteoporos Int 2011; 22(7): 2197-204.
  68. Lee YK, Lee EG, Kim HY, et al. Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis. Journal of Korean medical science 2020; 35(46): e403.
  69. Myint ZW, Momo HD, Otto DE, Yan D, Wang P, Kolesar JM. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis. JAMA network open 2020; 3(11): e2025826.
  70. Cosman F, Cauley JA, Eastell R, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? The Journal of clinical endocrinology and metabolism 2014; 99(12): 4546-54.
  71. Palermo A, D'Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N. Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int 2015; 26(8): 2073-89.
  72. Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, et al. Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis. The Journal of clinical endocrinology and metabolism 2017; 102(11): 3904-13.
  73. Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. Osteoporos Int 2012; 23(12): 2769-74.
  74. Lorentzon M, Branco J, Brandi ML, et al. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Adv Ther 2019; 36(10): 2811-24.
  75. Johansson H, Odén A, Kanis JA, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int 2014; 94(5): 560-7.
  76. Kanis JA, Johansson H, Harvey NC, et al. The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. Osteoporos Int 2021; 32(1): 47-54.
  77. McCloskey EV, Borgström F, Cooper C, et al. Short time horizons for fracture prediction tools: time for a rethink. Osteoporos Int 2021: in press.
  78. Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV. A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 2016; 11(1): 25.
  79. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. 2009; 339: b4229.
  80. National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture. NICE clinical guideline [CG146]. Manchester: NICE., 2012.
  81. National Institute for Health and Care Excellence (NICE). Osteoporosis: Quality standard [QS149]. Manchester, NICE, 2017.
  82. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011; 22(3): 809-16.
  83. Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 2012; 23(1): 75-85.
  84. Johansson H, Kanis JA, Odén A, et al. Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcified Tiss Inter 2014; 95(5): 428-35.
  85. McCloskey EV, Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Mineral Res 2016; 31(5): 940-8.
  86. Leslie WD, Lix LM, Morin SN, et al. Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. J Clin Densitom 2016; 19(3): 326-31.
  87. Masud T, Binkley N, Boonen S, Hannan MT. Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 2011; 14(3): 194-204.
  88. Johansson H, Odén A, Lorentzon M, et al. Is the Swedish FRAX model appropriate for Swedish immigrants? Osteoporos Int 2015; 26(11): 2617-22.
  89. Leslie WD, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. J Bone Mineral Res, 2018; 33(11): 1923-30.
  90. Wändell P, Li X, Carlsson AC, Sundquist J, Sundquist K. Osteoporotic fractures among foreign-born individuals: a national Swedish study. Osteoporosis International 2021; 32(2): 343-52.
  91. Brennan SL, Leslie WD, Lix LM, et al. FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporos Int 2014; 25(1): 61-9.
  92. Leslie WD, Orwoll ES, Nielson CM, et al. Estimated lean mass and fat mass differentially affect femoral bone density and strength index but are not FRAX independent risk factors for fracture. J Bone Mineral Res 2014; 29(11): 2511-9.
  93. Whitlock RH, Leslie WD, Shaw J, et al. The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. Kidney Int 2019; 95(2): 447-54.
  94. Baruch Fischhoff, Noel T. Brewer, Downs. JS. Communicating Risks and Benefits: An Evidence-Based User's Guide: US Department of Health and Human Services Food and Drug Administration.; 2018.
  95. Excellence. NIfHaC. NICE guideline [NG132]: Hyperparathyroidism (primary): diagnosis, assessment and initial management., 2019.
  96. Fink HA, Milavetz DL, Palermo L, et al. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 2005; 20(7): 1216-22.
  97. Melton LJ, 3rd, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999; 10(3): 214-21.
  98. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. Jama 2001; 285(3): 320-3.
  99. Jang HD, Kim EH, Lee JC, Choi SW, Kim K, Shin BJ. Current Concepts in the Management of Osteoporotic Vertebral Fractures: A Narrative Review. Asian Spine J 2020; 14(6): 898-909.
  100. Lewiecki EM. Bone densitometry and vertebral fracture assessment. Curr Osteoporos Rep 2010; 8(3): 123-30.
  101. Gausden EB, Nwachukwu BU, Schreiber JJ, Lorich DG, Lane JM. Opportunistic Use of CT Imaging for Osteoporosis Screening and Bone Density Assessment: A Qualitative Systematic Review. J Bone Joint Surg Am 2017; 99(18): 1580-90.
  102. Bromiley PA, Clark EM, Poole KE. Computer-Aided Diagnostic Systems for Osteoporotic Vertebral Fracture Detection: Opportunities and Challenges. J Bone Mineral Research 2020; 35(12): 2305-6.
  103. Kolanu N, Silverstone EJ, Ho BH, et al. Clinical Utility of Computer-Aided Diagnosis of Vertebral Fractures From Computed Tomography Images. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2020; 35(12): 2307-12.
  104. Howlett DC, Drinkwater KJ, Mahmood N, Illes J, Griffin J, Javaid K. Radiology reporting of osteoporotic vertebral fragility fractures on computed tomography studies: results of a UK national audit. Eur Radiol 2020; 30(9): 4713-23.
  105. Kim YM, Demissie S, Genant HK, et al. Identification of prevalent vertebral fractures using CT lateral scout views: a comparison of semi-automated quantitative vertebral morphometry and radiologist semi-quantitative grading. Osteoporos Int 2012; 23(3): 1007-16.
  106. Rubin KH, Rothmann MJ, Holmberg T, et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 2018; 29(3): 567-78.
  107. Merlijn T, Swart KM, van Schoor NM, et al. The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial. J Bone Miner Res 2019; 34(11): 1993-2000.
  108. Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 2020; 31(2): 251-7.
  109. Ismail AA, Cooper C, Felsenberg D, et al. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int 1999; 9(3): 206-13.
  110. Zhang Q, Dong J, Zhou D, Liu F. Comparative risk of fracture for bariatric procedures in patients with obesity: A systematic review and Bayesian network meta-analysis. International journal of surgery (London, England) 2020; 75: 13-23.
  111. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19(10): 1395-408.
  112. National Institute for Health and Care Excellence. Bisphosphonates for treating osteoporosis. Technology appraisal guidance [TA464]., 2019.
  113. McCloskey E, Kanis JA, Johansson H, et al. FRAX-based assessment and intervention thresholds--an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 2015; 26(8): 2091-9.
  114. Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 2018; 391(10122): 741-7.
  115. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016; 375(16): 1532-43.
  116. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377(15): 1417-27.
  117. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018; 391(10117): 230-40.
  118. Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 2020; 31(1): 1-12.
  119. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33(4): 522-32.
  120. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019; 30(1): 3-44.
  121. Johnell O, Oden A, Caulin F, Kanis JA. Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 2001; 12(3): 207-14.
  122. Giangregorio LM, Leslie WD. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2010; 25(6): 1400-5.
  123. Dretakis KE, Dretakis EK, Papakitsou EF, Psarakis S, Steriopoulos K. Possible Predisposing Factors for the Second Hip Fracture. Calcified Tissue International 1998; 62(4): 366-9.
  124. Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B. Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 2006; 17(9): 1353-7.
  125. Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P. Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2009; 24(7): 1299-307.
  126. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 2009; 68(1): 99-102.
  127. Johansson H, Siggeirsdóttir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int 2017; 28(3): 775-80.
  128. Kanis JA, Johansson H, Harvey NC, et al. The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture. Osteoporosis International 2021.
  129. Body JJ, Marin F, Kendler DL, et al. Efficacy of teriparatide compared with risedronate on FRAX(®)-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2020; 31(10): 1935-42.
  130. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357(18): 1799-809.
  131. Kanis JA, Johansson H, Harvey NC, et al. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines. Osteoporos Int 2021: 10.1007/s00198-021-5942-2.
  132. Kanis JA, Rizzoli R, Cooper C, Reginster JY. Challenges for the development of bone-forming agents in Europe. Calcif Tissue Int 2014; 94(5): 469-73.
  133. Johansson H, Kanis JA, Oden A, Compston J, McCloskey E. A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 2012; 23(3): 907-15.
  134. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24): 2077-82.
  135. Eastell R, Black DM, Boonen S, et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab, 2009; 94(9): 3215-25.
  136. Harvey NC, Kanis JA, Odén A, et al. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int 2015; 26(9): 2347-53.
  137. McCloskey E. A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. Osteoporos Int 2016; 27(1): 417-9.
  138. Reid IR, Horne AM, Mihov B, et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med, 2018; 379(25): 2407-16.
  139. Johansson H, Oden A, Johnell O, et al. Optimization of BMD measurements to identify high risk groups for treatment--a test analysis. J Bone Mineral Res 2004; 19(6): 906-13.
  140. Leslie WD, Majumdar SR, Lix LM, et al. High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 2012; 23(1): 391-7.
  141. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Mineral Research; 2012; 27(6): 1243-51.
  142. Fabiani R, Naldini G, Chiavarini M. Dietary Patterns in Relation to Low Bone Mineral Density and Fracture Risk: A Systematic Review and Meta-Analysis. Advances in nutrition (Bethesda, Md) 2019; 10(2): 219-36.
  143. Lin P-H, Ginty F, Appel LJ, et al. The DASH Diet and Sodium Reduction Improve Markers of Bone Turnover and Calcium Metabolism in Adults. The Journal of Nutrition 2003; 133(10): 3130-6.
  144. Groenendijk I, den Boeft L, van Loon LJC, de Groot L. High Versus low Dietary Protein Intake and Bone Health in Older Adults: a Systematic Review and Meta-Analysis. Computational and structural biotechnology journal 2019; 17: 1101-12.
  145. Darling AL, Manders RJF, Sahni S, et al. Dietary protein and bone health across the life-course: an updated systematic review and meta-analysis over 40 years. Osteoporosis International 2019; 30(4): 741-61.
  146. Myint MW, Wu J, Wong E, et al. Clinical benefits of oral nutritional supplementation for elderly hip fracture patients: a single blind randomised controlled trial. Age Ageing 2013; 42(1): 39-45.
  147. Iguacel I, Miguel-Berges ML, Gómez-Bruton A, Moreno LA, Julián C. Veganism, vegetarianism, bone mineral density, and fracture risk: a systematic review and meta-analysis. Nutrition reviews 2019; 77(1): 1-18.
  148. Tong TYN, Appleby PN, Armstrong MEG, et al. Vegetarian and vegan diets and risks of total and site-specific fractures: results from the prospective EPIC-Oxford study. BMC medicine 2020; 18(1): 353.
  149. Department of Health. Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. London: HMSO, 1991.
  150. Scientific Advisory Committee on Nutrition (SACN). Vitamin D and Health., 2016.
  151. Royal Osteoporosis Society. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. , 2018.
  152. Yao P, Bennett D, Mafham M, et al. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. JAMA network open 2019; 2(12): e1917789.
  153. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370(9588): 657-66.
  154. Group. DVDIPAoRT. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. Bmj 2010; 340: b5463.
  155. Harvey NC, Biver E, Kaufman JM, et al. The role of calcium supplementation in healthy musculoskeletal ageing. Osteoporosis International 2017; 28(2): 447-62.
  156. Kahwati LC, Weber RP, Pan H, et al. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 319(15): 1600-12.
  157. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303(18): 1815-22.
  158. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial. JAMA internal medicine 2016; 176(2): 175-83.
  159. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011; (7): Cd000333.
  160. Kemmler W, Shojaa M, Kohl M, von Stengel S. Effects of Different Types of Exercise on Bone Mineral Density in Postmenopausal Women: A Systematic Review and Meta-analysis. Calcif Tissue Int 2020; 107(5): 409-39.
  161. Babatunde OO, Bourton AL, Hind K, Paskins Z, Forsyth JJ. Exercise Interventions for Preventing and Treating Low Bone Mass in the Forearm: A Systematic Review and Meta-analysis. Arch Phys Med Rehabil 2020; 101(3): 487-511.
  162. Kelley GA, Kelley KS, Kohrt WM. Exercise and bone mineral density in men: a meta-analysis of randomized controlled trials. Bone 2013; 53(1): 103-11.
  163. Royal Osteoporosis Society. Strong, Steady and Straight; An Expert Consensus Statement on physical activity and exercise for osteoporosis., 2018.
  164. Kunutsor SK, Leyland S, Skelton DA, et al. Adverse events and safety issues associated with physical activity and exercise for adults with osteoporosis and osteopenia: A systematic review of observational studies and an updated review of interventional studies. Journal of frailty, sarcopenia and falls 2018; 3(4): 155-78.
  165. Bhasin S, Gill TM, Reuben DB, et al. A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries. N Engl J Med 2020; 383(2): 129-40.
  166. Lamb SE, Bruce J, Hossain A, et al. Screening and Intervention to Prevent Falls and Fractures in Older People. N Engl J Med 2020; 383(19): 1848-59.
  167. El-Khoury F, Cassou B, Charles M-A, Dargent-Molina P. The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials. 2013; 347: f6234.
  168. Sherrington C, Fairhall NJ, Wallbank GK, et al. Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev 2019; 1(1): Cd012424.
  169. Zhao R, Bu W, Chen X. The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions, and differing intervention protocols: a meta-analysis of randomized controlled trials. BMC Geriatr 2019; 19(1): 341.
  170. Sherrington C, Michaleff ZA, Fairhall N, et al. Exercise to prevent falls in older adults: an updated systematic review and meta-analysis. British journal of sports medicine 2017; 51(24): 1750-8.
  171. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012; (9): Cd007146.
  172. Jepsen DB, Thomsen K, Hansen S, Jørgensen NR, Masud T, Ryg J. Effect of whole-body vibration exercise in preventing falls and fractures: a systematic review and meta-analysis. BMJ Open 2017; 7(12): e018342.
  173. Thorin MH, Wihlborg A, Åkesson K, Gerdhem P. Smoking, smoking cessation, and fracture risk in elderly women followed for 10 years. Osteoporos Int 2016; 27(1): 249-55.
  174. Shen GS, Li Y, Zhao G, et al. Cigarette smoking and risk of hip fracture in women: a meta-analysis of prospective cohort studies. Injury 2015; 46(7): 1333-40.
  175. Wei Min, Rongze An, Songjun Li, Jiaying Feng, Jin Yang, Huang. Z. The effects of preoperative smoking cessation on the healing of fractures and postoperative complications: A systematic review and meta-analysis. Biomedical Research 2017; 28: 1883-9.
  176. Song TH, Shim JC, Jung DU, et al. Increased Bone Mineral Density after Abstinence in Male Patients with Alcohol Dependence. Clin Psychopharmacol Neurosci 2018; 16(3): 282-9.
  177. Health. Do. UK Chief Medical Officers’ Alcohol Guidelines Review Summary of the proposed new guidelines. Williams Lea, 2016.
  178. Crandall CJ, Newberry SJ, Diamant A, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 2014; 161(10): 711-23.
  179. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041): 1535-41.
  180. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343(9): 604-10.
  181. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339(5): 292-9.
  182. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282(14): 1344-52.
  183. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11(1): 83-91.
  184. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009; 24(4): 719-25.
  185. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67(4): 277-85.
  186. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15(6): 1006-13.
  187. Delmas PD, Recker RR, Chesnut CH, 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15(10): 792-8.
  188. Chesnut CH, 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241-9.
  189. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65(5): 654-61.
  190. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008; 35(3): 488-97.
  191. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809-22.
  192. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367(18): 1714-23.
  193. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373(9671): 1253-63.
  194. Reid IR, Horne AM, Mihov B, et al. Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women. J Bone Miner Res 2020; 35(1): 20-7.
  195. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010; 95(9): 4380-7.
  196. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 2018; 6(6): 445-54.
  197. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361(8): 756-65.
  198. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. The lancet Diabetes & endocrinology 2017; 5(7): 513-23.
  199. Langdahl BL, Teglbjaerg CS, Ho PR, et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 2015; 100(4): 1335-42.
  200. 2014. (accessed January 7th 2021).
  201. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. The Journal of clinical endocrinology and metabolism 2011; 96(4): 972-80.
  202. Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. The Journal of clinical endocrinology and metabolism 2011; 96(2): 394-402.
  203. Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. The Journal of clinical endocrinology and metabolism 2020.
  204. Cummings SR, Ferrari S, Eastell R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res; 2018; 33(2): 190-8.
  205. Dennison EM, Cooper C, Kanis JA, et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int 2019; 30(9): 1733-43.
  206. Reid IR, Horne AM, Mihov B, Gamble GD. Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Calcif Tissue Int 2017; 101(4): 371-4.
  207. Horne AM, Mihov B, Reid IR. Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up. Calcif Tissue Int 2019; 105(1): 107-8.
  208. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. J Bone Mineral Res; 2019; 34(12): 2220-8.
  209. Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. J Bone Miner Res: 2020; 35(7): 1207-15.
  210. Sølling AS, Harsløf T, Langdahl B. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial. J Bone Mineral Research 2020; 35(10): 1858-70.
  211. Makras P, Appelman-Dijkstra NM, Papapoulos SE, et al. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. The Journal of clinical endocrinology and metabolism 2021; 106(10): e4155-e62.
  212. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone 2017; 105: 11-7.
  213. Kendler D, Chines A, Clark P, et al. Bone Mineral Density After Transitioning From Denosumab to Alendronate. J Clin Endocrinol Metab, 2020; 105(3): e255-64.
  214. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; (7): CD004143.
  215. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-33.
  216. Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017; 318(22): 2234-49.
  217. Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int 2020; 31(12): 2271-86.
  218. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 1990; 113(9): 649-55.
  219. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282(7): 637-45.
  220. Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med 2009; 122(8): 754-61.
  221. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355(2): 125-37.
  222. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350(5): 459-68.
  223. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90(5): 2816-22.
  224. Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013; 98(2): 592-601.
  225. Osborne V, Layton D, Perrio M, Wilton L, Shakir SA. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf 2010; 33(7): 579-91.
  226. Agency EM. PSUR assessment report Strontium Ranelate. 2013.
  227. Blake GM, Compston JE, Fogelman I. Could strontium ranelate have a synergistic role in the treatment of osteoporosis? Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2009; 24(8): 1354-7.
  228. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434-41.
  229. Diez-Perez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodriguez M. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. Bone 2019; 120: 1-8.
  230. Simpson EL, Martyn-St James M, Hamilton J, et al. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis. Bone 2020; 130: 115081.
  231. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18(1): 9-17.
  232. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60(11): 3346-55.
  233. Kendler DL, Bone HG, Massari F, et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 2019; 30(12): 2437-48.
  234. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab; 2000; 85(6): 2129-34.
  235. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015; 386(9999): 1147-55.
  236. Cosman F, Crittenden DB, Ferrari S, et al. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. J Bone Mineral Res: 2018; 33(7): 1219-26.
  237. McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res 2018; 33(8): 1397-406.
  238. Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Research, 2019; 34(3): 419-28.
  239. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 2017; 390(10102): 1585-94.
  240. Keaveny TM, Crittenden DB, Bolognese MA, et al. Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass. J Bone Miner Research; 2017; 32(9): 1956-62.
  241. Ebina K, Hirao M, Tsuboi H, et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 2020; 140: 115574.
  242. Nayak S, Greenspan SL. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int 2019; 30(4): 705-20.
  243. National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management. NICE guideline [NG56]., 2016.
  244. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Research: 2016; 31(1): 16-35.
  245. Fink HA, MacDonald R, Forte ML, et al. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Ann Intern Med 2019; 171(1): 37-50.
  246. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Min Res, 2004; 19(8): 1259-69.
  247. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Jama 2006; 296(24): 2927-38.
  248. Ravn P, Christensen JO, Baumann M, Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone 1998; 22(5): 559-64.
  249. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19(3): 365-72.
  250. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Mineral Research 2012; 27(2): 243-54.
  251. Kim TY, Bauer DC, McNabb BL, et al. Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. J Bone Mineral Research, 2019; 34(5): 810-6.
  252. Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA internal medicine 2014; 174(7): 1126-34.
  253. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. Journal of Bone and Mineral Research 2015; 30(1): 3-23.
  254. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2007; 22(10): 1479-91.
  255. Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw: Dental Clinical Guidance., 2017.
  256. Salzman R, Hoza J, Perina V, Stárek I. Osteonecrosis of the external auditory canal associated with oral bisphosphonate therapy: case report and literature review. Otol Neurotol 2013; 34(2): 209-13.
  257. Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. Endocr Rev 2019; 40(2): 333-68.
  258. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Min Research 2010; 25(11): 2267-94.
  259. Shane E, Burr D, Abrahamsen B, et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2014; 29(1): 1-23.
  260. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Min Research, 2013; 28(8): 1729-37.
  261. Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. Bmj 2016; 353: i3365.
  262. van de Laarschot DM, McKenna MJ, Abrahamsen B, et al. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. J Clin Endocrin Metab 2020; 105(5): 1682-99.
  263. Carter M. Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting. J Clin Densitom 2019; 22(1): 25-30.
  264. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13(10): 777-87.
  265. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44(1): 202-11.
  266. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42(11): 2309-18.
  267. Deng J, Silver Z, Huang E, et al. Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatology (Oxford) 2020.
  268. Brown JE, Handforth C, Compston JE, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol 2020; 25: 100311.
  269. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97(6): 1802-22.
  270. Health NIf. Osteoporosis in Men. 2018.
  271. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87(8): 3656-61.
  272. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352(2): 154-64.
  273. Joseph JS, Lam V, Patel MI. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Eur Urol Oncol 2019; 2(5): 551-61.
  274. Poon Y, Pechlivanoglou P, Alibhai SMH, et al. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2018; 121(1): 17-28.
  275. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 Suppl 1: S3-18.
  276. Hadji P, Aapro MS, Body JJ, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 2017; 7: 1-12.
  277. Excellence NIfHaC. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates. 2017.
  278. Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 2021; 28: 100355.
  279. Miyashita H, Satoi S, Kuno T, Cruz C, Malamud S, Kim SM. Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Res Treat 2020; 181(2): 279-89.
  280. World Health Organization. Traitement de la douleur cancéreuse. Genève: Organisation mondiale de la Santé., 1987.
  281. Schofield P. The Assessment of Pain in Older People: UK National Guidelines. Age and Ageing 2018; 47(suppl_1): i1-i22.
  282. British Geriatric Society. Guidance on the management of pain in older people. Age and Ageing 2013; 42(suppl_1): i1-i57.
  283. Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int 2012; 23(1): 17-38.
  284. European Medicines Agency. European Medicines Agency recommends limiting long-term use of calcitonin medicines., 2012.
  285. Armingeat T, Brondino R, Pham T, Legré V, Lafforgue P. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 2006; 17(11): 1659-65.
  286. Gibbs JC, MacIntyre NJ, Ponzano M, et al. Exercise for improving outcomes after osteoporotic vertebral fracture. Cochrane Database of Systematic Reviews 2019; (7).
  287. Ebeling PR, Akesson K, Bauer DC, et al. The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report. 2019; 34(1): 3-21.
  288. Svensson HK, Olsson LE, Hansson T, Karlsson J, Hansson-Olofsson E. The effects of person-centered or other supportive interventions in older women with osteoporotic vertebral compression fractures-a systematic review of the literature. Osteoporos Int 2017; 28(9): 2521-40.
  289. Hofler RC, Jones GA. Bracing for Acute and Subacute Osteoporotic Compression Fractures: A Systematic Review of the Literature. World neurosurgery 2020; 141: e453-e60.
  290. Buchbinder R, Johnston RV, Rischin KJ, et al. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. Cochrane Database Syst Rev 2018; 11(11): Cd006349.
  291. Zambito A, Bianchini D, Gatti D, Rossini M, Adami S, Viapiana O. Interferential and horizontal therapies in chronic low back pain due to multiple vertebral fractures: a randomized, double blind, clinical study. Osteoporosis International 2007; 18(11): 1541-5.
  292. Axelsson KF, Johansson H, Lundh D, Möller M, Lorentzon M. Association Between Recurrent Fracture Risk and Implementation of Fracture Liaison Services in Four Swedish Hospitals: A Cohort Study. J Bone Miner Res 2020; 35(7): 1216-23.
  293. Wu CH, Tu ST, Chang YF, et al. Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: A systematic literature review and meta-analysis. Bone 2018; 111: 92-100.
  294. Department of Health. Fracture prevention services - an economic evaluation. 2009.
  295. NHS_RightCare. Falls and Fragility Fractures Pathway. , 2017.
  296. Javaid MK, Kyer C, Mitchell PJ, et al. Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture(R) Best Practice Framework tool. Osteoporos Int 2015; 26(11): 2573-8.
  297. Royal Osteoporosis Society. Effective Secondary Prevention of Fragility Fractures: Clinical Standards for Fracture Liaison Services , 2019.
  298. Ganda K, Puech M, Chen J. S, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporosis International 2013; 24(2): 393-406.
  299. Ganda K, Mitchell PJ, Seibel MJ. Chapter 3, Models of Secondary Fracture Prevention: Systematic review and Metaanalysis of Outcomes. In: Mitchell PJ, Seibel MJ, eds. Secondary Fracture Prevention, an International Perspective: Elsevier Inc; 2019: 33-62.
  300. Wu CH, Chen CH, Chen PH, et al. Identifying characteristics of an effective fracture liaison service: systematic literature review. Osteoporos Int 2018; 29(5): 1023-47.
  301. Public Health England. Falls and fracture consensus statement: Supporting commissioning for prevention, 2017.
  302. Royal Osteoporosis Society. Clinical Guidance for the Effective Identification of Vertebral Fractures, 2017.
  303. Laurna Bullock, Fay Crawford-Manning, Elizabeth Cottrell, et al. Co-designing a model Fracture Liaison Service consultation with patients, carers and clinicians: a Delphi survey to inform the content of the i-FraP complex consultation intervention. Archives in Osteoporosis 2021; in press.
  304. Paskins Z, Torres Roldan VD, Hawarden AW, et al. Quality and effectiveness of osteoporosis treatment decision aids: a systematic review and environmental scan. Osteoporos Int 2020.
  305. National Institute for Health and Care Excellence. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical Guideline [CG76]., 2009.
  306. Cornelissen D, de Kunder S, Si L, et al. Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int 2020; 31(9): 1645-69.
  307. Martin J, Viprey M, Castagne B, et al. Interventions to improve osteoporosis care: a systematic review and meta-analysis. Osteoporos Int 2020; 31(3): 429-46.
  308. Clynes MA, Westbury LD, Dennison EM, et al. Bone densitometry worldwide: a global survey by the ISCD and IOF. Osteoporos Int 2020; 31(9): 1779-86.
  309. Foundation TH. Quality improvement made simple: What everyone should know about health care quality improvement. The Health Foundation, 8 Salisbury Square, London, 2021.
  310. Javaid MK, Harvey NC, McCloskey E, Kanis JA, C C. Assessment and management of imminent fracture risk in the setting of the fracture liaison service. Osteo Internat 2021; in press.
  311. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66(7): 719-25.
  312. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. 2008; 337: a744.
  313. National Institute for Health and Care Excellence. The guidelines manual. Process and methods [PMG6]. Section 9 Developing and wording guideline recommendations, 2012.
  314. Nayak S, Greenspan SL. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. J Am Geriatr Soc 2017; 65(3): 490-5.
  315. Zeng LF, Pan BQ, Liang GH, et al. Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials. Frontiers in pharmacology 2019; 10: 882.
  316. Wang YK, Zhang YM, Qin SQ, et al. Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018; 97(42): e12691.
  317. Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther 2019; 13: 2843-52.